Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors

Business Wire November 3, 2020

Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)

Business Wire October 30, 2020

ADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares

Business Wire October 9, 2020

New Ventures Funds Rebrands as Scientia Ventures

PR Newswire October 2, 2020

ADC Therapeutics Announces Pricing of Public Offering

Business Wire September 23, 2020

ADC Therapeutics Announces Proposed Public Offering

Business Wire September 21, 2020

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire September 21, 2020

ADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020

Business Wire September 17, 2020

ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers

Business Wire September 10, 2020

ADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131

Business Wire September 4, 2020

ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights

Business Wire August 18, 2020

ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020

Business Wire August 12, 2020

ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib

Business Wire July 17, 2020

ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

Business Wire July 6, 2020

New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO

PR Newswire June 30, 2020

ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Business Wire June 12, 2020

ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress

Business Wire June 5, 2020